Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis

Clinical Infectious Diseases(2024)10.1093/cid/ciae024Source: DataRank Database

Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.13)OA: hybridTopics (57)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Belén P. Solans ORCID,Paolo Denti ORCID,Louvina E. van der Laan ORCID,H. Simon Schaaf ORCID,Bryan Vonasek ORCID

Live enrichment

PubMed:38340060 PMC:PMC10954342 OpenAlex:https://openalex.org/W4391718878

NIH HHS

Grant: T32GM007546

National Institutes of Health

Grant: 2T32GM007546-49

Clinical Pharmacology, Drug Action and Pharmacogenetics

FWCI

2.13

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae024/56657851/ciae024.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae024/56657851/ciae024.pdf

journalhttps://doi.org/10.1093/cid/ciae024

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38340060

repositoryhttps://escholarship.org/uc/item/4z66n38r

Fields of Study

Tuberculosis Research and EpidemiologyPharmaceutical studies and practicesAntibiotics Pharmacokinetics and Efficacy03 medical and health sciences0302 clinical medicine

MeSH Terms

AdultAntitubercular AgentsChildHumansInfantInfant, NewbornRifampinTabletsTuberculosis, Multidrug-ResistantLevofloxacin

Keywords

MedicineLevofloxacinDosingPharmacokineticsRifampicinTuberculosisMeta-analysisPharmacologyDrugIntensive care medicineAntibioticsInternal medicinePathologyMicrobiologyPediatricsDrug-resistant TuberculosisAdultClinical SciencesAntitubercular Agents610Medical and Health SciencesRare DiseasesClinical Research615Tuberculosis, Multidrug-ResistantMajor ArticleHumansChildBiomedical and Clinical SciencesPreventionInfant, NewbornInfantMultidrug-ResistantBiological SciencesNewbornEmerging Infectious DiseasesInfectious DiseasesGood Health and Well Being6.1 PharmaceuticalsAntimicrobial ResistanceRifampinTablets

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being